trending Market Intelligence /marketintelligence/en/news-insights/trending/FRZxd6WDfmQ_vJX_2ZCTIg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Bellicum selling certain assets to Texas-based cancer center for $15M

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Bellicum selling certain assets to Texas-based cancer center for $15M

Bellicum Pharmaceuticals Inc. will sell certain assets to the University of Texas MD Anderson Cancer Center for $15 million.

Under the deal, the cancer center will acquire the Houston-based biopharmaceutical company's approximately 60,000-square-foot manufacturing facility in Houston, including manufacturing, office and laboratory space.

MD Anderson will hire about 35 employees from the company's technical operations and quality staff.

Bellicum Pharmaceuticals will also enter into a master services agreement with the cancer center.

The cancer center will use the facility for its own internal programs and for manufacturing Bellicum's cellular therapy programs, such as GoCAR technology, for clinical trials and possible early commercial supply.

GoCAR-T, or BPX-601, is a chimeric antigen receptor T cell product designed to be more effective with its capability to override key immune inhibitory mechanisms. CAR-T therapy involves taking a patient's T cells, a type of immune system cell, and changing them in the laboratory so they will attack cancer cells.

Bellicum President and CEO Rick Fair said the agreement will provide the company access to cell therapy product supply and will reduce its operating expenses.

The facility's sale is likely to close in the first quarter of 2020, subject to some conditions such as the building landlord's consent.